How does diabetes accelerate Alzheimer disease pathology?
暂无分享,去创建一个
Eva L. Feldman | E. Feldman | Bhumsoo Kim | A. Rosko | Catrina Sims-Robinson | Bhumsoo Kim | Andrew Rosko | C. Sims-Robinson
[1] J. Ávila,et al. Analysis of microtubule-associated protein tau glycation in paired helical filaments. , 1994, The Journal of biological chemistry.
[2] G. Biessels,et al. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment , 1998, Brain Research.
[3] W. Markesbery,et al. p38 Kinase Is Activated in the Alzheimer's Disease Brain , 1999, Journal of neurochemistry.
[4] D L Alkon,et al. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. , 2005, Biochemical Society transactions.
[5] J. L. François,et al. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease , 2001, Neuroscience.
[6] A. Meinders,et al. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. , 2003, Atherosclerosis.
[7] P. Kostyuk,et al. Diabetes-induced changes in calcium homeostasis and the effects of calcium channel blockers in rat and mice nociceptive neurons , 2001, Diabetologia.
[8] Geert Jan Biessels,et al. The effects of type 1 diabetes on cognitive performance: a meta-analysis. , 2005, Diabetes care.
[9] M. Kehry,et al. CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. , 2001, International immunology.
[10] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[11] Clay B. Holroyd,et al. Potential roles of insulin and IGF-1 in Alzheimer ’ s disease , 2003 .
[12] D. Bennett,et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.
[13] B. Hemmings,et al. Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.
[14] R. Studer,et al. Effect of diabetes on hormone-stimulated and basal hepatocyte calcium metabolism. , 1989, Endocrinology.
[15] D. Butterfield,et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease , 2007, Brain Research.
[16] M. Kennedy,et al. Hippocampal Neurons Predisposed to Neurofibrillary Tangle Formation Are Enriched in Type II Calcium/Calmodulin-Dependent Protein Kinase , 1990, Journal of neuropathology and experimental neurology.
[17] J. Sowers,et al. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? , 1994, The American journal of medicine.
[18] J. Wands,et al. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.
[19] Johanna Kuusisto,et al. Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study , 1997, BMJ.
[20] P. O'Brien,et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.
[21] J. Kushner,et al. Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation , 2003, The Journal of Neuroscience.
[22] J. Luchsinger,et al. Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms , 2007, The Journal of Neuroscience.
[23] A. Zmijewska,et al. Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.
[24] V. Lee,et al. Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons* , 1997, The Journal of Biological Chemistry.
[25] S. Hoyer,et al. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis , 1998, Journal of Neural Transmission.
[26] L. Murri,et al. Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.
[27] P. Moreira,et al. Insulin protects against amyloid β-peptide toxicity in brain mitochondria of diabetic rats , 2005, Neurobiology of Disease.
[28] V. Giguère,et al. Phosphatases at the heart of FoxO metabolic control. , 2008, Cell metabolism.
[29] A. Levey,et al. Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance , 2006, Cellular and Molecular Life Sciences CMLS.
[30] Z. Khachaturian. Calcium Hypothesis of Alzheimer's Disease and Brain Aging a , 1994, Annals of the New York Academy of Sciences.
[31] K. Davis,et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.
[32] S. Craft,et al. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. , 2004, European journal of pharmacology.
[33] E. Masliah,et al. Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits , 2008, The Journal of Neuroscience.
[34] Wei⁃qin Zhao,et al. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. , 2009, Biochimica et biophysica acta.
[35] C. Cotman,et al. Caspase-9 Activation and Caspase Cleavage of tau in the Alzheimer's Disease Brain , 2002, Neurobiology of Disease.
[36] I. Deary,et al. Is Type II Diabetes Associated With an Increased Risk of Cognitive Dysfunction?: A critical review of published studies , 1997, Diabetes Care.
[37] S. Faraone,et al. Diabetes and overweight associate with non‐APOE4 genotype in an alzheimer's disease population , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[38] A. Zmijewska,et al. Physiological and Pathological Changes in Glucose Regulate Brain Akt and Glycogen Synthase Kinase-3* , 2005, Journal of Biological Chemistry.
[39] R. Dean,et al. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.
[40] R. Schliebs,et al. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology , 2004, International Journal of Developmental Neuroscience.
[41] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[42] A. Sima,et al. Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes , 2007, Diabetes.
[43] K. Jellinger,et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.
[44] R. Powers,et al. Transglutaminase activity is increased in Alzheimer's disease brain , 1997, Brain Research.
[45] Eva L Feldman,et al. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. , 2009, Endocrinology.
[46] Z. Makita,et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. , 1998, The American journal of pathology.
[47] E. Masliah,et al. Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin , 2008, Journal of neuroscience research.
[48] E. Feldman,et al. Oxidative stress in the pathogenesis of diabetic neuropathy. , 2004, Endocrine reviews.
[49] G. Johnson,et al. The role of tau phosphorylation and cleavage in neuronal cell death. , 2007, Frontiers in bioscience : a journal and virtual library.
[50] J. Saczynski,et al. The Honolulu-Asia Aging Study , 2007 .
[51] L. Launer,et al. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.
[52] Christian Hölscher,et al. Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.
[53] R. Kalaria,et al. Nϵ-Carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease , 2004 .
[54] T B Shea,et al. Calcium‐Activated Neutral Proteinase (Calpain) System in Aging and Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.
[55] R. J. Williams,et al. Elemental analysis of neurofibrillary tangles in Alzheimer's disease using proton-induced X-ray analysis. , 1992, Ciba Foundation symposium.
[56] D. D. McKinley,et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease , 2001, Brain Research Bulletin.
[57] S. Goodman,et al. Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.
[58] T. Hilbum,et al. From top to bottom , 1995 .
[59] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[60] C. Brayne,et al. Vascular Risks and Incident Dementia: Results from a Cohort Study of the Very Old , 1998, Dementia and Geriatric Cognitive Disorders.
[61] R. Jemmerson,et al. Calcium‐induced Cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane , 2002, Journal of neurochemistry.
[62] K. Nakashima,et al. [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[63] L. Plum,et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. , 2005, Diabetes.
[64] George Perry,et al. Oxidative stress in diabetes and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[65] D. Sparks,et al. Cholesterol Accumulates in Senile Plaques of Alzheimer Disease Patients and in Transgenic APPsw Mice , 2001, Journal of neuropathology and experimental neurology.
[66] G. Getz,et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.
[67] Wu Haibo. A 6-year follow-up study of Cerec3 computer aided design and computer aided manufacture of all-ceramic crowns on implants , 2012 .
[68] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[69] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. Götz,et al. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models , 2004, International Journal of Developmental Neuroscience.
[71] M. Haan. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease , 2006, Nature Clinical Practice Neurology.
[72] W. Noble,et al. Kinase activities increase during the development of tauopathy in htau mice , 2007, Journal of neurochemistry.
[73] M. Harris. Hypercholesterolemia in Diabetes and Glucose Intolerance in the U.S. Population , 1991, Diabetes Care.
[74] J. Götz,et al. Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2009, PloS one.
[75] I. Björkhem,et al. Oxysterols and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.
[76] Ronald C Petersen,et al. Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.
[77] 吉武毅人. Incidence and risk factors of vascular dementia and Alzheimer′s disease in a defined elderly Japanese population: The Hisayama Study(一般住民中の高齢者における脳血管性痴呆アルツハイマー病の発症率と危険因子の検討: 久山町研究) , 1997 .
[78] R. Green,et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.
[79] J. Blass,et al. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. , 1991, Revue neurologique.
[80] W. Noble,et al. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. , 2003, Brain research. Molecular brain research.
[81] C. Masters,et al. Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42 , 2005, The Journal of Neuroscience.
[82] S S Furuie,et al. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer’s disease: a combined MRI and SPECT study , 2002, Journal of neurology, neurosurgery, and psychiatry.
[83] F. Schmidt. Meta-Analysis , 2008 .
[84] M. Zemel,et al. Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. , 1989, The American journal of medicine.
[85] C. Cotman,et al. Apolipoprotein‐E Genotyping of Diabetic Dementia Patients: Is Diabetes Rare in Alzheimer's Disease? , 1996, Journal of the American Geriatrics Society.
[86] D. Henze,et al. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. , 2006, Current topics in medicinal chemistry.
[87] P. Moreira,et al. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes , 2007, Journal of the Neurological Sciences.
[88] P. Barber,et al. Diabetes, leukoencephalopathy and rage , 2006, Neurobiology of Disease.
[89] S. Craft,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.
[90] W. Klein,et al. Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.
[91] R. Martins,et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.
[92] A. Ott. Risk of dementia: The Rotterdam Study , 1997 .
[93] M. Reger,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[94] C. Morrison. Leptin signaling in brain: A link between nutrition and cognition? , 2009, Biochimica et biophysica acta.
[95] Ryuichi Morishita,et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.
[96] P. Scheltens,et al. Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.
[97] Tony Wyss-Coray,et al. Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.
[98] M. Beal,et al. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.
[99] D. Alkon,et al. Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.
[100] Jing He,et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. , 2002, Diabetes.
[101] K. Rockwood,et al. Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.
[102] G. Johnson,et al. Tau phosphorylation in neuronal cell function and dysfunction , 2004, Journal of Cell Science.
[103] M. Mattson,et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. , 1999, Science.
[104] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[105] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[106] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[107] P. Moreira,et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. , 2008, Free radical biology & medicine.
[108] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[109] Claude Messier,et al. The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function , 2004, Journal of clinical and experimental neuropsychology.
[110] J. Heitner,et al. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects , 1997, Neurology.
[111] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[112] A. Hofman,et al. Insulin and Cognitive Function in an Elderly Population: The Rotterdam Study , 1997, Diabetes Care.
[113] R. Berry,et al. Tau polymerization: role of the amino terminus. , 2003, Biochemistry.
[114] E. Masliah,et al. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.
[115] Gopal Thinakaran,et al. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments , 2006, Neurology.
[116] N. Zilka,et al. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats , 2007, Brain Research.
[117] G. Johnson,et al. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons , 2000, Neuroscience.
[118] Prasanthi,et al. Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .
[119] C. Bondy,et al. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. , 2005, Endocrinology.
[120] C. Cotman,et al. The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology , 2005, Journal of neuropathology and experimental neurology.
[121] D. Praticò,et al. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.
[122] M. Brownlee,et al. Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.
[123] Robert C. Wolpert,et al. A Review of the , 1985 .
[124] Raj Kalaria,et al. N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. , 2004, Free radical biology & medicine.
[125] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[126] B. Hyman,et al. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. , 2000, The Journal of biological chemistry.
[127] M. Robin,et al. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.
[128] B. Hyman,et al. Modulation of β-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP) , 2000, The Journal of Biological Chemistry.
[129] Jongsoon Lee,et al. The role of GSK3 in glucose homeostasis and the development of insulin resistance. , 2007, Diabetes research and clinical practice.
[130] D. Jo,et al. Proapoptotic Effects of Tau Cleavage Product Generated by Caspase-3 , 2001, Neurobiology of Disease.
[131] H. Shimano,et al. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. , 2008, Journal of lipid research.
[132] E. Feldman,et al. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance , 2008, Neurobiology of Disease.
[133] L S Honig,et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease , 2005, Neurology.
[134] A. Korczyn. The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.
[135] G. Hart,et al. O-GlcNAc modification in diabetes and Alzheimer's disease. , 2007, Molecular bioSystems.
[136] J. Ordovás,et al. Familial apolipoprotein E deficiency. , 1986, The Journal of clinical investigation.
[137] Christina A. Wilson,et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.
[138] G. Biessels,et al. Ageing and diabetes: implications for brain function. , 2002, European journal of pharmacology.
[139] G. Paolisso,et al. Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.
[140] K. Yaffe. Metabolic syndrome and cognitive decline. , 2007, Current Alzheimer research.
[141] S. Katsuki. [Hisayama study]. , 1971, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
[142] Robert B. Petersen,et al. Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.
[143] I. Grundke‐Iqbal,et al. Brain glucose transporters, O‐GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease , 2009, Journal of neurochemistry.
[144] C. Schweiger. [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[145] Virginia M. Y. Lee,et al. Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.
[146] C. Lines,et al. Rofecoxib , 2004, Neurology.
[147] Z. Makita,et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease , 2001, Brain Research.
[148] Sunita Sharma,et al. Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling , 2008, Neurobiology of Disease.
[149] A. Ammit,et al. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease , 2010, Neuropharmacology.
[150] D. Selkoe,et al. Calcium ionophore increases amyloid beta peptide production by cultured cells. , 1994, Biochemistry.
[151] T. Pozzan,et al. Mitochondria as biosensors of calcium microdomains. , 1999, Cell calcium.
[152] W. Noble,et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[153] Rong Wang,et al. Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.
[154] T. Ohm,et al. Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons , 2001, Acta Neuropathologica.
[155] D. Small,et al. Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.